Insider trades
James M. Frates, CFO of Amylyx Pharmaceuticals AMLX, has filed 1 purchase and 15 sales on the open market. Over the past 12 months that comes to a net sale of $358.6K. The latest trade was on 03/05.
James M. Frates
CFO
- Company
- Amylyx Pharmaceuticals AMLX
- First filing
- 23/01/04
- Trades
- 49 trades
- Buys / sales
- 1 / 15
- 12-month net buying
- −$358.6K
- Last trade
- 03/05
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
| Open-market sale | 03/02 | 03/04 | 7,909 sh | $14.52 | $114,838.68 | −4.6% | |
| Open-market sale | 02/02 | 02/04 | 3,557 sh | $14.65 | $52,110.05 | −2.0% | |
| Open-market sale | 01/06 | 01/08 | 3,326 sh | $11.11 | $36,951.86 | −1.8% | |
| Open-market sale | 25/09/30 | 25/10/02 | 10,558 sh | $14.65 | $154,674.7 | −3.6% | |
| Open-market sale | 25/03/31 | 25/04/02 | 10,896 sh | $3.47 | $37,809.12 | −3.6% | |
| Open-market buy | 24/09/12 | 24/09/16 | 40,000 sh | $2.53 | $101,200 | +20.7% | |
| Open-market sale | 24/03/05 | 24/03/07 | 1,792 sh | $18.73 | $33,564.16 | −1.3% | |
| Open-market sale | 24/01/09 | 24/01/11 | 2,716 sh | $16.33 | $44,352.28 | −2.4% | |
AMLX | Open-market sale10b5-1 plan | 23/05/16 | 23/05/18 | 32,500 sh2 trades | $26.94avg. | $875,560 | −36.9% |
AMLX | Open-market saleAmendment | 23/03/16 | 23/03/24 | 32,500 sh2 trades | $31.89avg. | $1,036,472.4 | −48.9% |
AMLX | Open-market sale | 23/03/16 | 23/03/20 | 32,500 sh2 trades | $31.89avg. | $1,036,472.4 | −95.6% |
AMLX | Open-market sale | 23/01/06 | 23/01/10 | 2,658 sh2 trades | $36.30avg. | $96,484.26 | +8.5% |